205 related articles for article (PubMed ID: 11158765)
1. Comparative toxicities and pharmacokinetics of intrathecal lipid (amphotericin B colloidal dispersion) and conventional deoxycholate formulations of amphotericin B in rabbits.
Clemons KV; Sobel RA; Williams PL; Stevens DA
Antimicrob Agents Chemother; 2001 Feb; 45(2):612-5. PubMed ID: 11158765
[TBL] [Abstract][Full Text] [Related]
2. Comparative pharmacokinetics and safety of a novel lyophilized amphotericin B lecithin-based oil-water microemulsion and amphotericin B deoxycholate in animal models.
Brime B; Frutos P; Bringas P; Nieto A; Ballesteros MP; Frutos G
J Antimicrob Chemother; 2003 Jul; 52(1):103-9. PubMed ID: 12805269
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of alternative dosing regimens of poly-aggregated amphotericin B.
Espada R; Valdespina S; Molero G; Dea MA; Ballesteros MP; Torrado JJ
Int J Antimicrob Agents; 2008 Jul; 32(1):55-61. PubMed ID: 18534826
[TBL] [Abstract][Full Text] [Related]
4. Safety evaluation of ABELCET, an amphotericin B lipid complex (ABLC): toxicity studies in rats.
Zhang Z; Diener RM; Lipman JM
Int J Toxicol; 2006; 25(4):285-94. PubMed ID: 16815817
[TBL] [Abstract][Full Text] [Related]
5. Amphotericin B formulations: a comparative review of efficacy and toxicity.
Hamill RJ
Drugs; 2013 Jun; 73(9):919-34. PubMed ID: 23729001
[TBL] [Abstract][Full Text] [Related]
6. Study of the toxicity of a new lipid complex formulation of amphotericin B.
Larabi M; Pages N; Pons F; Appel M; Gulik A; Schlatter J; Bouvet S; Barratt G
J Antimicrob Chemother; 2004 Jan; 53(1):81-8. PubMed ID: 14657087
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of amphotericin B lipid complex in a rabbit model of coccidioidal meningitis.
Capilla J; Clemons KV; Sobel RA; Stevens DA
J Antimicrob Chemother; 2007 Sep; 60(3):673-6. PubMed ID: 17646202
[TBL] [Abstract][Full Text] [Related]
8. Lipid formulations of amphotericin B as first-line treatment of zygomycosis.
Petrikkos GL
Clin Microbiol Infect; 2009 Oct; 15 Suppl 5():87-92. PubMed ID: 19754765
[TBL] [Abstract][Full Text] [Related]
9. Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations.
Groll AH; Lyman CA; Petraitis V; Petraitiene R; Armstrong D; Mickiene D; Alfaro RM; Schaufele RL; Sein T; Bacher J; Walsh TJ
Antimicrob Agents Chemother; 2006 Oct; 50(10):3418-23. PubMed ID: 17005824
[TBL] [Abstract][Full Text] [Related]
10. Influence of albumin dialysis on pharmacokinetics of amphotericin B colloidal dispersion and amphotericin B lipid complex.
Weiler S; Vogelsinger H; Joannidis M; Dunzendorfer S; Bellmann R
Artif Organs; 2011 Jun; 35(6):667-71. PubMed ID: 21668831
[TBL] [Abstract][Full Text] [Related]
11. Toxicities and pharmacokinetics of subconjunctival injection of liposomal amphotericin B.
Kaji Y; Yamamoto E; Hiraoka T; Oshika T
Graefes Arch Clin Exp Ophthalmol; 2009 Apr; 247(4):549-53. PubMed ID: 19043733
[TBL] [Abstract][Full Text] [Related]
12. Lipid-based antifungal agents: a concise overview.
Arikan S
Cell Mol Biol Lett; 2002; 7(3):919-22. PubMed ID: 12378276
[TBL] [Abstract][Full Text] [Related]
13. Comparison of conventional and lipid emulsion formulations of amphotericin B: Pharmacokinetics and toxicokinetics in dogs.
Nieto J; Alvar J; Rodríguez C; San Andrés MI; San Andrés MD; González F
Res Vet Sci; 2018 Apr; 117():125-132. PubMed ID: 29272720
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation.
Gershkovich P; Wasan EK; Lin M; Sivak O; Leon CG; Clement JG; Wasan KM
J Antimicrob Chemother; 2009 Jul; 64(1):101-8. PubMed ID: 19398459
[TBL] [Abstract][Full Text] [Related]
15. Comparative toxicity and concentrations of intravitreal amphotericin B formulations in a rabbit model.
Cannon JP; Fiscella R; Pattharachayakul S; Garey KW; De Alba F; Piscitelli S; Edward DP; Danziger LH
Invest Ophthalmol Vis Sci; 2003 May; 44(5):2112-7. PubMed ID: 12714650
[TBL] [Abstract][Full Text] [Related]
16. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation.
Espada R; Valdespina S; Dea MA; Molero G; Ballesteros MP; Bolás F; Torrado JJ
J Antimicrob Chemother; 2008 May; 61(5):1125-31. PubMed ID: 18285313
[TBL] [Abstract][Full Text] [Related]
17. [Nephrotoxicity of amphotericin B].
Deray G; Mercadal L; Bagnis C
Nephrologie; 2002; 23(3):119-22. PubMed ID: 12087808
[TBL] [Abstract][Full Text] [Related]
18. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
Khan MA; Owais M
J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
[TBL] [Abstract][Full Text] [Related]
19. Biodistribution and tissue toxicity of amphotericin B in mice following multiple dose administration of a novel oral lipid-based formulation (iCo-009).
Gershkovich P; Sivak O; Wasan EK; Magil AB; Owen D; Clement JG; Wasan KM
J Antimicrob Chemother; 2010 Dec; 65(12):2610-3. PubMed ID: 20861140
[TBL] [Abstract][Full Text] [Related]
20. Comparative tissue distribution and elimination of amphotericin B colloidal dispersion (Amphocil) and Fungizone after repeated dosing in rats.
Wang LH; Fielding RM; Smith PC; Guo LS
Pharm Res; 1995 Feb; 12(2):275-83. PubMed ID: 7784345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
